MRI-Based Assessment of the Pharyngeal Constrictor Muscle as a Predictor of Surgical Margin after Transoral Robotic Surgery in HPV-Positive Tonsillar Cancer

References

1. 1.↵
   1. Chaturvedi AK,
   2. Engels EA,
   3. Pfeiffer RM, et al

   . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–301 doi:10.1200/JCO.2011.36.4596 pmid:21960503

   Abstract/FREE Full Text
2. 2.↵
   1. Morisod B,
   2. Venara V, II.,
   3. Alzuphar S, et al

   . Minimizing adjuvant treatment after transoral robotic surgery through surgical margin revision and exclusion of radiographic extracapsular extension: a prospective observational cohort study. Head Neck 2017;39:965–73 doi:10.1002/hed.24712 pmid:28188953

   CrossRefPubMed
3. 3.↵
   1. Persky MJ,
   2. Albergotti WG,
   3. Rath TJ, et al

   . Positive margins by oropharyngeal subsite in transoral robotic surgery for T1/T2 squamous cell carcinoma. Otolaryngol Head Neck Surg 2018;158:660–66 doi:10.1177/0194599817742852 pmid:29182490

   CrossRefPubMed
4. 4.↵
   1. Ang KK,
   2. Sturgis EM

   . Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012;22:128–42 doi:10.1016/j.semradonc.2011.12.004 pmid:22385920

   CrossRefPubMed
5. 5.↵
   1. Baskin RM,
   2. Boyce BJ,
   3. Amdur R, et al

   . Transoral robotic surgery for oropharyngeal cancer: patient selection and special considerations. Cancer Manag Res 2018;10:839–46 doi:10.2147/CMAR.S118891 pmid:29719420

   CrossRefPubMed
6. 6.↵
   1. Park YM,
   2. Jung CM,
   3. Cha D, et al

   . A new clinical trial of neoadjuvant chemotherapy combined with transoral robotic surgery and customized adjuvant therapy for patients with T3 or T4 oropharyngeal cancer. Ann Surg Oncol 2017;24:3424–29 doi:10.1245/s10434-017-6001-5 pmid:28718033

   CrossRefPubMed
7. 7.↵
   1. Mirghani H,
   2. Blanchard P

   . Treatment de-escalation for HPV-driven oropharyngeal cancer: where do we stand? Clin Transl Radiat Oncol 2018;8:4–11 doi:10.1016/j.ctro.2017.10.005 pmid:29594236

   CrossRefPubMed
8. 8.↵
   1. Masterson L,
   2. Moualed D,
   3. Liu ZW, et al

   . De-escalation treatment protocols for humanpapillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 2014;50:2636–48 doi:10.1016/j.ejca.2014.07.001 pmid:25091798

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Chen AM,
   2. Felix C,
   3. Wang PC, et al

   . Reduced-dose radiotherapy for humanpapillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, Phase 2 study. Lancet Oncol 2017;18:803–11 doi:10.1016/S1470-2045(17)30246-2 pmid:28434660

   CrossRefPubMed
10. 10.↵
    1. Mallen-St Clair J,
    2. Alani M,
    3. Wang MB, et al

    . Human papillomavirus in oropharyngeal cancer: the changing face of a disease. Biochim Biophys Acta 2016;1866:141–50 doi:10.1016/j.bbcan.2016.07.005 pmid:27487173

    CrossRefPubMed
11. 11.↵
    1. Eisbruch A,
    2. Schwartz M,
    3. Rasch C, et al

    . Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004;60:1425–39 doi:10.1016/j.ijrobp.2004.05.050 pmid:15590174

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Rieger JM,
    2. Zalmanowitz JG,
    3. Wolfaardt JF

    . Functional outcomes after organ preservation treatment in head and neck cancer: a critical review of the literature. Int J Oral Maxillofac Surg 2006;35:581–87 doi:10.1016/j.ijom.2006.03.026 pmid:16697144

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Machtay M,
    2. Moughan J,
    3. Trotti A, et al

    . Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–89 doi:10.1200/JCO.2007.14.8841 pmid:18559875

    Abstract/FREE Full Text
14. 14.↵
    1. Bhayani MK,
    2. Holsinger FC,
    3. Lai SY

    . A shifting paradigm for patients with head and neck cancer: transoral robotic surgery (TORS). Oncology (Williston Park) 2010;24:1010–15 pmid:21155450

    PubMed
15. 15.↵
    1. Mydlarz WK,
    2. Chan JY,
    3. Richmon JD

    . The role of surgery for HPV-associated head and neck cancer. Oral Oncol 2015;51:305–13 doi:10.1016/j.oraloncology.2014.10.005 pmid:25456011

    CrossRefPubMed
16. 16.↵
    1. Duek I,
    2. Billan S,
    3. Amit M, et al

    . Transoral robotic surgery in the HPV era. Rambam Maimonides Med J 2014;5:e0010 doi:10.5041/RMMJ.10144 pmid:24808948

    CrossRefPubMed
17. 17.↵
    1. Holsinger FC,
    2. McWhorter AJ,
    3. Ménard M, et al

    . Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region, I: technique, complications, and functional results. Arch Otolaryngol Head Neck Surg 2005;131:583–91 doi:10.1001/archotol.131.7.583 pmid:16027280

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Moore EJ,
    2. Janus J,
    3. Kasperbauer J

    . Transoral robotic surgery of the oropharynx: clinical and anatomic considerations. Clin Anat 2012;25:135–41 doi:10.1002/ca.22008 pmid:22109715

    CrossRefPubMed
19. 19.↵
    1. Chen MM,
    2. Roman SA,
    3. Kraus DH, et al

    . Transoral robotic surgery: a population-level analysis. Otolaryngol Head Neck Surg 2014;150:968–75 doi:10.1177/0194599814525747 pmid:24618503

    CrossRefPubMed
20. 20.↵
    1. An Y,
    2. Park HS,
    3. Kelly JR, et al

    . The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 2017;123:2762–72 doi:10.1002/cncr.30598 pmid:28323338

    CrossRefPubMed
21. 21.↵
    1. Zhan KY,
    2. Eskander A,
    3. Kang SY, et al

    . Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base. Oral Oncol 2017;73:152–59 doi:10.1016/j.oraloncology.2017.08.020 pmid:28939068

    CrossRefPubMed
22. 22.↵
    NCCN Clinical Practice Guideline Sin Oncology. 2018 Version I.2018. https://www.firsthospital.cn/upload/doc/201911/21175519.pdf. Accessed May 13, 2018
23. 23.↵
    1. Fleiss J,
    2. Levin B,
    3. Paik MC

    . Statistical Methods for Rates and Proportions. 2nd ed. John Wiley; 1981:38–46
24. 24.↵
    1. DeLong ER,
    2. DeLong DM,
    3. Clarke-Pearson DL

    . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45 doi:10.2307/2531595 pmid:3203132

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Heinze G,
    2. Schemper M

    . A solution to the problem of monotone likelihood in Cox regression. Biometrics 2001;57:114–19 doi:10.1111/j.0006-341x.2001.00114.x pmid:11252585

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Cracchiolo JR,
    2. Roman BR,
    3. Kutler DI, et al

    . Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. J Surg Oncol 2016;114:405–11 doi:10.1002/jso.24353 pmid:27392812

    CrossRefPubMed
27. 27.↵
    1. Moore EJ,
    2. Van Abel KM,
    3. Price DL, et al

    . Transoral robotic surgery for oropharyngeal carcinoma: surgical margins and oncologic outcomes. Head Neck 2018;40:747–55 doi:10.1002/hed.25055 pmid:29327784

    CrossRefPubMed
28. 28.↵
    1. Funk RK,
    2. Moore EJ,
    3. Garcia JJ, et al

    . Risk factors for locoregional relapse after transoral robotic surgery for human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck 2016;38(Suppl 1):E1674–79 doi:10.1002/hed.24298 pmid:26667985

    CrossRefPubMed
29. 29.↵
    1. Cracchiolo JR,
    2. Baxi SS,
    3. Morris LG, et al

    . Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer 2016;122:1523–32 doi:10.1002/cncr.29938 pmid:26970050

    CrossRefPubMed
30. 30.↵
    1. Weinstein GS,
    2. O'Malley BW Jr.,
    3. Rinaldo A, et al

    . Understanding contraindications for transoral robotic surgery (TORS) for oropharyngeal cancer. Eur Arch Otorhinolaryngol 2015;272:1551–52 doi:10.1007/s00405-014-3331-9 pmid:25327689

    CrossRefPubMed
31. 31.↵
    1. Chan JY,
    2. Tsang RK,
    3. Eisele DW, et al

    . Transoral robotic surgery of the parapharyngeal space: a case series and systematic review. Head Neck 2015;37:293–98 doi:10.1002/hed.23557 pmid:24288351

    CrossRefPubMed